-
Product Insights
NewAirway Management Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Airway Management Pipeline Market Report Overview Airway management refers to medical procedures performed for the prevention or alleviation of any obstruction in the airway. Airway management procedures are performed to open a pathway for maintaining or re-storing proper gas exchange between a patient's lungs and the atmosphere. This is accomplished with the use of an infraglottic device (Endotracheal tubes) supraglottic device (Laryngeal mask) or surgical method (Tracheostomy). The devices used for airway management are referred to as airway management devices....
-
Product Insights
Marburgvirus Infections (Marburg Hemorrhagic Fever) – Drugs In Development, 2023
Global Markets Direct’s, ‘Marburgvirus Infections (Marburg Hemorrhagic Fever) - Drugs In Development, 2023’, provides an overview of the Marburgvirus Infections (Marburg Hemorrhagic Fever) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Marburgvirus Infections (Marburg Hemorrhagic Fever), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Mycobacterium tuberculosis Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Mycobacterium tuberculosis Infections - Drugs In Development, 2023’, provides an overview of the Mycobacterium tuberculosis Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mycobacterium tuberculosis Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Tuberculosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Tuberculosis - Drugs In Development, 2023’, provides an overview of the Tuberculosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Tuberculosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Ebolavirus Infections (Ebola Hemorrhagic Fever) – Drugs In Development, 2023
Global Markets Direct’s, ‘Ebolavirus Infections (Ebola Hemorrhagic Fever) - Drugs In Development, 2023’, provides an overview of the Ebolavirus Infections (Ebola Hemorrhagic Fever) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Lassa Fever (Lassa Hemorrhagic Fever) – Drugs In Development, 2023
Global Markets Direct’s, ‘Lassa Fever (Lassa Hemorrhagic Fever) - Drugs In Development, 2023’, provides an overview of the Lassa Fever (Lassa Hemorrhagic Fever) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Lassa Fever (Lassa Hemorrhagic Fever), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Track & Monitor
Innovation in Pharmaceuticals: HIV peptides
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s HIV peptides segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based on...
-
Track & Monitor
Innovation in Pharmaceuticals: rtRNA virus peptides
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s rtRNA virus peptides segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based...
-
Product Insights
Glycoprotein 41 (gp41) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Glycoprotein 41 pipeline drugs market research report outlays comprehensive information on the Glycoprotein 41 (gp41) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics development with respective active and dormant or discontinued projects.
-
Sector Analysis
Outlook for Viral Vector Contract Manufacturing – Gene Therapies, Cell Therapies, and COVID-19 Vaccines
The bio/pharmaceutical industry is experiencing a shortage of viral vectors, a component needed to produce gene therapies and gene-modified cell therapies, as well as certain COVID-19 vaccines that require a viral vector, notably those from AstraZeneca and Johnson & Johnson (J&J). This report reveals that viral vector production is limited by insufficient manufacturing capacity, an inefficient manufacturing process, and the requirement for complex specialist facilities. There are 14 therapies/vaccines that use a viral vector (gene therapies, gene-modified cell therapies, and...